NHS Expands Access to Life-Extending Breast Cancer Drug in England

London, England — The National Health Service (NHS) in England has initiated widespread provision of a life-extending drug, Enhertu, for patients with advanced, incurable breast cancer. The National Institute for Health and Care Excellence (NICE) issued approval for the treatment's use following a period of negotiation.

Enhertu targets HER2-low metastatic breast cancer, a subtype accounting for approximately half of all metastatic breast cancer cases. The drug functions by delivering chemotherapy directly to cancer cells while minimizing damage to healthy tissue. Clinical trials indicated that Enhertu extended patients' lives by an average of six months compared to traditional chemotherapy.

NICE initially declined to recommend Enhertu in 2022 due to concerns regarding its cost-effectiveness. However, further discussions between the drug's manufacturer, Daiichi Sankyo, and the NHS resulted in an agreement. This agreement lowered the drug's price, enabling NICE to reverse its initial decision and recommend Enhertu for routine use.

Richard Hughes, Director of Real World Affairs at Daiichi Sankyo UK, stated the company has worked with NICE and NHS England to make the treatment available to patients. Helen Knight, Director of Medicines Evaluation at NICE, confirmed the agency's positive recommendation for Enhertu as an option for adults with unresectable or metastatic HER2-low breast cancer after prior chemotherapy.

Breast cancer remains the most common cancer in the UK. Approximately 56,000 women and 400 men receive a diagnosis each year. Metastatic breast cancer, where the cancer has spread to other parts of the body, affects an estimated 35,000 people in the UK. This advanced stage of the disease is considered incurable.

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, acknowledged the initial disappointment surrounding the previous decision. She welcomed the announcement, noting that Enhertu offers a significant new treatment option for patients with HER2-low metastatic breast cancer. "This decision will offer hope to thousands of women and men living with this devastating disease," Morgan stated.

Professor Peter Johnson, National Clinical Director for Cancer at NHS England, described Enhertu as an effective new treatment. He emphasized the NHS's commitment to making the latest cancer drugs available to patients. The availability of Enhertu provides a new therapeutic avenue for individuals facing an incurable diagnosis.